RTOG to Conduct Multicenter Study of Prostate Brachytherapy

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 11
Volume 7
Issue 11

PHILADELPHIA--The Radiation Therapy Oncology Group (RTOG) has just begun work on a potentially ground-breaking study of the use of radioactive seed implants (brachytherapy) for cancer that is confined to the prostate gland. The study will be the first multi-institutional evaluation of the treatment. To date, a number of single-institution studies have been conducted, showing the technique to be effective in controlling the disease.

PHILADELPHIA--The Radiation Therapy Oncology Group (RTOG) has just begun work on a potentially ground-breaking study of the use of radioactive seed implants (brachytherapy) for cancer that is confined to the prostate gland. The study will be the first multi-institutional evaluation of the treatment. To date, a number of single-institution studies have been conducted, showing the technique to be effective in controlling the disease.

The new RTOG investigation will look closely at the potential side effects of prostate brachytherapy as well as its effectiveness, said Colleen Lawton, MD, study chair. Dr. Lawton is a radiation oncologist at the Medical College of Wisconsin, Milwaukee.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
According to Ronan J. Kelly, deciding whether to give nivolumab- or durvalumab-based regimens in gastric cancers may rely on a patient’s frailty.
More follow-up data will better elucidate the impact of frontline use of hypomethylating agents in patients with myelodysplastic syndromes.
Five-year follow-up revealed that patients treated with nivolumab vs placebo in the phase 3 CheckMate 577 trial experienced a “doubling” of survival.
Patients treated with nivolumab in the phase 3 CheckMate 577 trial were less likely to experience progression-related treatment discontinuation vs placebo.
2 experts in this video
Related Content